Selecta Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

Selecta Biosciences (NASDAQ: SELB), based in Watertown, MA, will share a corporate update and hold one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The presentation is scheduled for February 18, 2022, at 1:00 p.m. EST. Selecta is known for its ImmTOR™ platform, which is utilized to develop tolerogenic therapies aimed at reducing unwanted immune responses. An archived webcast will be available for those interested in further information.

WATERTOWN, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 11^th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

SVB Leerink 11^th Annual Global Healthcare conference
Format: Presentation and one-on-one investor meetings
Presentation Date: Friday February 18^th, 2022
Presentation Time: 1:00 p.m. EST
Webcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com 

FAQ

What is Selecta Biosciences announcing at the SVB Leerink conference on February 18, 2022?

Selecta Biosciences will provide a corporate update and engage in one-on-one investor meetings.

What time will Selecta Biosciences present at the SVB Leerink conference?

Selecta Biosciences is scheduled to present at 1:00 p.m. EST on February 18, 2022.

How can I access the webcast for Selecta Biosciences' conference presentation?

The webcast will be available on Selecta Biosciences' website under the Investors & Media section.

What is the focus of Selecta Biosciences' ImmTOR™ platform?

The ImmTOR™ platform aims to develop tolerogenic therapies that selectively mitigate unwanted immune responses.

Where is Selecta Biosciences headquartered?

Selecta Biosciences is headquartered in the Greater Boston area.